DOCSLIB.ORG

293 Y. Nakasato and R.L. Yung (Eds.), Geriatric Rheumatology: A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
293 Y. Nakasato and R.L. Yung (Eds.), Geriatric Rheumatology: A Index A variability, 233 Abatacept, 67 classification criteria Absolute fracture risk model (FRAX), 242 clinical, 232 Acetaminophen, 62, 75 laboratary, 232 aCL ELISA tests, 233 clinical and subclinical atherosclerosis, 20 Acupuncture, 54 features, 231 Acute gouty arthritis therapy, 209 morbidity and mortality, 232–233 Acute pseudogout precipitators, elderly, 216 Anti-TNF agents Aerobic exercise, 109, 125, 126, 128, 261 adalimumab, 164 AION, 226 efficacy, 164 Alcoholic myopathy, 270 etanercept, 164 Amyloid myopathy, 269–270 infliximab, 165 Anakinra, 67 safety, 164 Analgesics, 52–53 Anti-TNF alpha agents, 66–67 ANCA-associated renal vasculitis Anti-TNFa(alpha) therapy, 37 age indicator, 202 Apoptosis, 4 cyclophosphamide dose, 202 APS. See Antiphospholipid syndrome (APS) diagnosis, 32 Arthritis-specific federal policy initiatives morbidity and mortality determinant, 201 CDC Arthritis Program, 97 therapy, 32 Healthy People 2010, 96 Angiotensin converting enzyme (ACE), 262 The National Arthritis Action Plan, 96–97 Ankylosing Spondylitis (AS), 109–110 National Arthritis Act of 1974, 95–96 atherosclerosis, 20–21 National Arthritis Plan of 1976, 95–96 clinical features, 104 National Institute of Arthritis, 96 inspiratory muscle training, 110 Arthrocentesis pathology, 110 corticosteroids, 113–114 physical therapy interventions, 104 elbow sacroilitis, 110 joint effusion, 118 self-management, 110 olecranon bursa injection, 118 Anticonvulsants, 52 tennis elbow injection, 118 Antidepressants, 51–52 foot Antimalarials ankle injection (tibio-talar), 121 clinical pharmacology, 154 metatarsophalangeal joint injection, 122 efficacy, 154–155 Morton’s neuroma, 122 safety, 155 plantar fasciitis injection, 121 Antineutrophil cytoplasmic antibodies, 198 posterior tibialis tendon sheath injection, 121–122 Antiphospholipid (aPL) antibodies hip, 120 diseases, 233–234 hyaluronates, 114 elderly, 234–236 indications, 113 Antiphospholipid syndrome (APS) knee injection, 120–121 aCL antibodies, prevalence local anesthetics, 114 aCL ELISA tests, 233 post injection care, 116 Louisville reference standards, 233 precautions and contraindications, 115 venous thromboembolism, 233 shoulder aPL antibodies, prevalence acromioclavicular joint (ACJ) injection, 117 autoimmune diseases, 233 biceps tendon injection, 117–118 elderly, 234–236 glenohumeral joint injection, 116 non-parametric tests, 233 subacromial-subdeltoid (SA-AD) bursal injection, 116–117 SLE patients, 233 suprascapular nerve block, 117 transient ischemic attacks and strokes, 233 side effects and complications, 114–115 Y. Nakasato and R.L. Yung (eds.), Geriatric Rheumatology: A Comprehensive Approach, 293 DOI 10.1007/978-1-4419-5792-4, © Springer Science+Business Media, LLC 2011 294 Index Arthrocentesis (cont.) anatomy and physiology, 11 technical considerations, 115–116 fracture healing, 12–13 wrist and hand remodeling, 241 carpal tunnel injection, 118–119 resorption, 241 De Quervain’s tenosynovitis injection, 120 senile osteoporosis, 11–12 first carpometacarpal (CMC) joint, 119 Bone mineral density (BMD), 179 ganglion, 119 Bone remodeling, 241 metcarpophalangeal and proximal interphalangeal Bone resorption, 241 joints injection, 119 Boost test, 39 trigger finger injection, 119–120 Bracing or splinting, 77 Arthroplasty, 82 BRMs. See Biologic response modifiers (BRMs) Atherosclerosis ankylosing spondylitis, 20–21 antiphospholipid syndrome (APS), 20 C ASCVD, epidemiology of, 19–20 Calcium-containing crystal-associated arthropathies. See Calcium atheroma, 17 pyrophosphate dihydrate (CPPD) deposition disease clinical implications, preventive strategies Calcium pyrophosphate dihydrate (CPPD) antimalarial agents, 22 deposition disease biological therapies, 22 and BCP pathogenesis, 218–219 corticosteroids, 21 clinical spectrum, 214–215 methotrexate, 22 diagnosis mycophenolate mofetil, 22 characteristic rhomboid shape demonstration, 216 NSAIDs and COX–2 inhibitors, 21 MSKUS, 216–217 statins, 21–22 epidemiology, 213 pathologic mechanisms, SLE and RA, 18–19 osteoarthritis and, 215 primary systemic vasculitis, 21 treatment psoriasis and psoriatic arthritis, 20 acute pseudogout attack management, 217 shared disease mechanisms, 17–18 biologic therapy, 218 systemic sclerosis, 21 colchicine or corticosteroids, 218 Atherosclerotic cardiovascular disease (ASCVD) dietary calcium, 218 endothelial dysfunction, 18 hydroxychloroquine or methotrexate, 218 epidemiology magnesium, 218 RA and ASCVD mortality, 19 NSAIDs, 217 SLE and ASCVD mortality, 19 probenecid, 218 subclinical atherosclerosis in SLE and RA, 19–20 Cataracts, medium-and small-vessel vasculitis, 203–204 pathologic mechanisms, 18–19 Cevimeline, 290 Autoimmunity, 290 Chloroquine, 66 Azathioprine, 66 Churg-Strauss syndrome (CSS), 200 CNS angiitis diagnosis, 32–33 B therapy, 33 Barthels Index, 88 Cognitive-behavioral therapy (CBT), 53 Basic calcium phosphate (BCP) diseases Colchicine, 209, 270 and CPPD pathogenesis, 219–220 Comorbid psychiatric disorders, 53 Milwaukee shoulder syndrome, 219 Complementary and alternative medicine (CAM) practices, 77 B cells, 6 Corticosteroids, 21, 270 Biologic response modifiers (BRMs), 159–167 CPPD. See Calcium pyrophosphate dihydrate (CPPD) deposition abatacept, 166 disease anakinra, 166–167 Cryotherapy, 76 cancer, older RA patient, 163–164 Crystal arthropathies, 179 other safety concerns, 164 Crystal induced inflammation, 220 rituximab, 167 Cyclooxygenase–2 (COX–2) inhibitors, 21 TNF-a(alpha) action, 159 Cyclophosphamide, 282, 290 TNF inhibiting agents, older RA patient, 163 Cyclosporin, 66, 289–290 Biomechanic factors knee laxity, 180 LLI, 180–181 D proprioception, 181 Degenerative lumbar spinal stenosis (LSS) Bisphosphonate therapy classification, 102 males, 242 definition, 102 osteonecrosis of jaw, 244 pathophysiology, 103 BMD. See Bone mineral density (BMD) physical examination findings and interventions Bone Maine lumbar spine study, 105 age-related changes sensory and proprioceptive changes, 102 cytokines, 12 therapeutic exercise, 104–105 GH-IGF axis, 12 Dendritic cells (DC), 6 vitamin D, 14–15 Depot corticosteroid crystals, 221 Index 295 Dermatomyositis (DM) differential diagnosis autoantibodies, 265, 266 ESR and C-reactive protein (CRP), 146 diagnosis, 265 pro-inflammatory cytokine pattern, 146 incidence rates, 265 radiographic evaluation, 146 malignancy, 266–267 seropositive patients, 146 Deyo-Charlson Comorbidity Index, 211 serum rheumatoid factor (RF), 146 Disease-modifying anti-rheumatic drug (DMARD) inflammatory arthritis, 145 antimalarials symptoms, 145 clinical pharmacology, 154 treatment, 147–149 efficacy, 154–155 Electrical stimulation, 76 safety, 155 Enzyme-linked immunosorbent assay (ELISA), 233 anti-TNF agents Eosinophilic fasciitis (EF), 279 adalimumab, 164 Exercise, 110 efficacy, 164 aerobic, 109, 125, 126, 128 etanercept, 164 characterization, 125 infliximab, 165 definition, 125 safety, 164 degenerative LSS, 104 biologic response modifiers and fall prevention, 243–244 abatacept, 166 interventions, 98, 107 anakinra, 166–167 muscle strengthening, 126, 128 cancer, older RA patient, 163–164 nursing home patient, 77 other safety concerns, 164 range-of-motion, 102 rituximab, 167 sarcopenia, 261 TNF-a(alpha) action, 159 stabilization and closed chain, 102 TNF inhibiting agents, older RA patient, 163 Eye dryness. See Xeropthalmia introduction, 151–152 Ezetimibe, 270 leflunomide clinical pharmacology, 155 efficacy, 156 F safety, 156 Facioscapulohumeral dystrophy, 267 methotrexate Febuxostat, 210 clinical pharmacology, 156–157 Fibrates, 270 efficacy, 157 Fibric acid derivatives, 270 safety, 157–158 Fibromyalgia syndrome (FMS) physiologic changes with aging chronic pain assessment, 46–47 pharmacodynamics, 153–154 classification criteria, 45 pharmacokinetics, 152–153 clinical presentation, 47 sulfasalazine definition and epidemiology, 45–46 clinical pharmacology, 158 differential diagnosis, 48, 49 efficacy, 158 pain processing and analgesia, 46 safety, 158–159 pathogenesis, 46 Disease modifying anti-rheumatic drugs (DMARDs), 147 physical examination, 47–48 azathioprine, 66 prevalence, 45 chloroquine, 66 signs and symptoms, 47 cyclosporine, 66 treatment hydroxychloroquine, 66 analgesics, 52–53 leflunomide, 65–66 anticonvulsants, 52 methotrexate, 65 antidepressants, 51–52 sulfasalazine, 66 comorbid psychiatric disorders, 53 Drug-induced myopathy non-pharmacological management, 53–54 alcoholic myopathy, 270 Fluoxetine, 52 colchicine, 270 Fracture healing, 12–13 corticosteroids, 270 Fragility fracture, osteoporosis, 241 lipid lowering agents, 270 Frailty and Injuries: Cooperative Studies of Intervention Techniques statin drugs, 270–271 (FICSIT) studies, 126 Duloxetine, 52 G E Gadolinium, 279 Elderly onset rheumatoid arthritis GCA. See Giant cell arteritis (GCA) aging factors, 147 Geriatric Depression Scale, 88 characterization, 145 Geriatric gout management clinical features accurate diagnosis, 209 de novo development, 145 acute gouty arthritis therapy, 209 disease duration, 146 in elderly patients physical examination, 146 drug adherence rates, 210 vs.YORA, 146 health care costs, 211 296 Index Geriatric gout management (cont.) T-cell migration, 5 hyperuricemia treatment Th1 and Th2 responses, 5 allopurinol, 210 Th17 cells, 5 febuxostat, 210 vaccine efficacy, elder patients, 7 serum urate level, 209–210 Immunosenescence, 7 Geriatric rheumatology adaptive immunity definition, 86 B-cells, 253–254 future aspects, 89–90 Gavazzi and Krause postulate, 254 Gerontorheumatology outpatient service (GOS) memory T-cells, 253 aims
Load more

Recommended publications
  • Eosinophilic Fasciitis: an Atypical Presentation of a Rare Disease
    AT BED SIDE Eosinophilic fasciitis: an atypical presentation of a rare disease Catia Cabral1,2 António Novais1 David Araujo2 Ana Mosca2 Ana Lages2 Anna Knock2 1. Internal Medicine Service, Centro Hospitalar Tondela-Viseu, Viseu, Portugal 2. Internal Medicine Service, Hospital de Braga, Braga, Portugal http://dx.doi.org/10.1590/1806-9282.65.3.326 SUMMARY Eosinophilic fasciitis, or Shulman’s disease, is a rare disease of unknown etiology. It is characterized by peripheral eosinophilia, hyper- gammaglobulinemia, and high erythrocyte sedimentation rate. The diagnosis is confirmed by a deep biopsy of the skin. The first line of treatment is corticotherapy. We present a rare case of eosinophilic fasciitis in a 27-year-old woman with an atypical presentation with symmetrical peripheral ede- ma and a Groove sign. The patient responded well to treatment with corticosteroids at high doses and, in this context, was associated with hydroxychloroquine and azathioprine. After two and a half years, peripheral eosinophilia had increased, and more of her skin had hardened. At that time, the therapy was modified to include corticoids, methotrexate, and penicillamine. It is of great importance to publicize these cases that allow us to gather experience and better treat our patients. KEYWORDS: Fasciitis. Eosinophils. Eosinophilia. Edema/etiology. INTRODUCTION Eosinophilic fasciitis is a rare disease character- among individuals of 40-50 years old and no associa- ized by skin alterations such as scleroderma, pe- tions of race, risk factors, or family history.3 ripheral eosinophilia, hypergammaglobulinemia, The importance of this case is related to the rar- and high erythrocyte sedimentation rate.1 It more ity of the disease, its atypical presentation, and the frequently involves the inferior limbs.
    [Show full text]
  • Assessment of Skin, Joint, Tendon and Muscle Involvement
    Assessment of skin, joint, tendon and muscle involvement A. Akesson1, G. Fiori2, T. Krieg3, F.H.J. van den Hoogen4, J.R. Seibold5 1Lund University Hospital, Lund, Sweden; ABSTRACT The extent of skin involvement is also 2Istituto di Clinica Medica IV, Florence, This rep o rt makes re c o m m e n d at i o n s the prime clinical criterion for the sub- Italy; 3University of Cologne, Koln, for standardized techniques of data ga - classification of SSc into its two princi- 4 Germany; University Medical Centre t h e ring and collection rega rd i n g : 1 ) pal subsets – SSc with diffuse cuta- St. Raboud, Nijmegen, The Netherlands; 5UMDNJ Scleroderma Program, skin involvement 2) joint and tendon in - neous involvement (diffuse scleroder- New Brunswick, New Jersey, USA. volvement, and 3) involvement of the ma) and SSc with limited cutaneous Anita Akesson, MD, PhD; Ginevra Fiori, skeletal muscles. The recommendations i nvo l vement (limited scl e ro d e rma – MD; Thomas Krieg, MD; Frank H.J. van in this report derive from a critical re - p rev i o u s ly termed the “CREST syn- den Hoogen, MD, PhD; James R. Seibold, v i ew of the ava i l able literat u re and drome”) (3). By consensus and conven- MD. group discussion. Committee re c o m - t i o n , p atients with skin invo l ve m e n t Please address correspondence to: mendations are considered appropriate restricted to sites distal to the elbows James R. Seibold, MD, Professor and for descri p t ive clinical inve s t i gat i o n , and knees, exclusive of the face, are Director, UMDNJ Scleroderma Program, translational studies and as standards considered to have limited scleroderma MEB 556 51 French Street, New for clinical practice.
    [Show full text]
  • Conditions Related to Inflammatory Arthritis
    Conditions Related to Inflammatory Arthritis There are many conditions related to inflammatory arthritis. Some exhibit symptoms similar to those of inflammatory arthritis, some are autoimmune disorders that result from inflammatory arthritis, and some occur in conjunction with inflammatory arthritis. Related conditions are listed for information purposes only. • Adhesive capsulitis – also known as “frozen shoulder,” the connective tissue surrounding the joint becomes stiff and inflamed causing extreme pain and greatly restricting movement. • Adult onset Still’s disease – a form of arthritis characterized by high spiking fevers and a salmon- colored rash. Still’s disease is more common in children. • Caplan’s syndrome – an inflammation and scarring of the lungs in people with rheumatoid arthritis who have exposure to coal dust, as in a mine. • Celiac disease – an autoimmune disorder of the small intestine that causes malabsorption of nutrients and can eventually cause osteopenia or osteoporosis. • Dermatomyositis – a connective tissue disease characterized by inflammation of the muscles and the skin. The condition is believed to be caused either by viral infection or an autoimmune reaction. • Diabetic finger sclerosis – a complication of diabetes, causing a hardening of the skin and connective tissue in the fingers, thus causing stiffness. • Duchenne muscular dystrophy – one of the most prevalent types of muscular dystrophy, characterized by rapid muscle degeneration. • Dupuytren’s contracture – an abnormal thickening of tissues in the palm and fingers that can cause the fingers to curl. • Eosinophilic fasciitis (Shulman’s syndrome) – a condition in which the muscle tissue underneath the skin becomes swollen and thick. People with eosinophilic fasciitis have a buildup of eosinophils—a type of white blood cell—in the affected tissue.
    [Show full text]
  • Eosinophilic Fasciitis (Shulman Syndrome)
    CONTINUING MEDICAL EDUCATION Eosinophilic Fasciitis (Shulman Syndrome) Sueli Carneiro, MD, PhD; Arles Brotas, MD; Fabrício Lamy, MD; Flávia Lisboa, MD; Eduardo Lago, MD; David Azulay, MD; Tulia Cuzzi, MD, PhD; Marcia Ramos-e-Silva, MD, PhD GOAL To understand eosinophilic fasciitis to better manage patients with the condition OBJECTIVES Upon completion of this activity, dermatologists and general practitioners should be able to: 1. Recognize the clinical presentation of eosinophilic fasciitis. 2. Discuss the histologic findings in patients with eosinophilic fasciitis. 3. Differentiate eosinophilic fasciitis from similarly presenting conditions. CME Test on page 215. This article has been peer reviewed and is accredited by the ACCME to provide continuing approved by Michael Fisher, MD, Professor of medical education for physicians. Medicine, Albert Einstein College of Medicine. Albert Einstein College of Medicine designates Review date: March 2005. this educational activity for a maximum of 1 This activity has been planned and implemented category 1 credit toward the AMA Physician’s in accordance with the Essential Areas and Policies Recognition Award. Each physician should of the Accreditation Council for Continuing Medical claim only that credit that he/she actually spent Education through the joint sponsorship of Albert in the activity. Einstein College of Medicine and Quadrant This activity has been planned and produced in HealthCom, Inc. Albert Einstein College of Medicine accordance with ACCME Essentials. Drs. Carneiro, Brotas, Lamy, Lisboa, Lago, Azulay, Cuzzi, and Ramos-e-Silva report no conflict of interest. The authors report no discussion of off-label use. Dr. Fisher reports no conflict of interest. We present a case of eosinophilic fasciitis, or Shulman syndrome apart from all other sclero- Shulman syndrome, in a 35-year-old man and dermiform states.
    [Show full text]
  • A Rare Paraneoplastic Syndrome in a Patient with Prostate Carcinoma
    Case Report J Med Cases. 2020;11(9):267-270 Palmar Fasciitis and Polyarthritis Syndrome: A Rare Paraneoplastic Syndrome in a Patient With Prostate Carcinoma Anouk G. de Boera, d, Ruth Klaasenb, Marlies C. van der Goesc, Haiko J. Bloemendala Abstract Keywords: Palmar fasciitis; Polyarthritis; Paraneoplastic; Prostate cancer A 73-year-old patient was seen in our hospital for treatment of meta- static adenocarcinoma of the prostate (pT1aN0M1a R0, BRCA-2 gene mutation). Prostatectomy and regional radiotherapy were performed and goserelin, a luteinizing hormone-releasing hormone (LHRH) Introduction analog, had been started because of disease progression. Castra- tion-resistant progressive disease developed, and enzalutamide was added. A decrease of the prostate-specific antigen (PSA) level was Palmar fasciitis and polyarthritis syndrome (PFPAS) is an achieved. Before the start of enzalutamide, the patient developed uncommon paraneoplastic syndrome. It is characterized by bilateral pain and stiffness of both hands combined with thickening rapid onset of bilateral arthritis of the hands and fasciitis of of the hands. The symptoms progressed rapidly to bilateral flexion the palms. PFPAS causes diffuse painful swollen hands and is and extension contractures. The patient became unable to tie his characteristically recognized by progressive stiffness and con- shoelaces and had to use adjusted cutlery to eat. Consultation of the tractures [1]. These progressive flexion contractures can lead rheumatologist, X-rays, ultrasound and palmar skin biopsy of the to a loss of hand function. hands were performed. The clinical picture resembles descriptions PFPAS is mostly described as a paraneoplastic syndrome of “palmar fasciitis and polyarthritis syndrome” (PFPAS), a rare in patients with ovarian carcinoma [1].
    [Show full text]
  • Subscapular Bursitis As a Rare Manifestation of Dermatomyositis: a Case Report Kyung Rok Kim1, Maximilian F
    DOI: 10.5152/eurjrheum.2015.0083 Case Report Subscapular bursitis as a rare manifestation of dermatomyositis: a case report Kyung Rok Kim1, Maximilian F. Konig2, Jin Kyun Park1 Abstract Dermatomyositis (DM) is characterized by proximal muscle weakness and characteristic skin rash. Pain is a less common feature and usu- ally indicates inflammation of extramuscular structures such as fascia. Here we report a rare case of subscapular bursitis in a 48-year-old woman with DM. She initially presented with severe, sharp, stabbing pain in her right shoulder that worsened with shoulder movement. Magnetic resonance imaging (MRI) revealed inflammation in the right subscapular bursae. A few months later, the patient developed peri- ungual erythema, Gottron’s papules, and shawl sign with muscle pain in her thighs. DM was diagnosed based on the presence of interface dermatitis on skin biopsy and diffuse muscle inflammation on MRI. Bursitis and myalgia responded incompletely to nonste roidal anti-in- flammatory drugs but promptly to corticosteroids. Here we report a case of subscapular bursitis as a rare manifestation of DM. Pain in pa- tients with DM may warrant physicians to evaluate for the presence of additional inflammatory processes in the perimuscular structures. Keywords: Dermatomyositis, bursitis, pain Introduction Dermatomyositis (DM) is a chronic autoimmune disease involving muscles and skin as the main target of inflammation (1). While proximal muscle weakness is the key musculoskeletal feature, pain is not common in idiopathic inflammatory myopathy. Therefore, pain often indicates involvement of extramuscular struc- tures. Bursitis, inflammation of the bursae, is painful and extremely rare in DM (2, 3). Here we report a unique case of subscapular bursitis as the initial presentation of DM.
    [Show full text]
  • Nonvascular Extremity Ultrasound ______
    Comments and Responses Regarding Draft Local Coverage Determination: Nonvascular Extremity Ultrasound _______________________________________________________________________ As an important part of Medicare Local Coverage Determination (LCD) development, National Government Services solicits comments from the provider community and from members of the public who may be affected by or interested in our LCDs. The purpose of the advice and comment process is to gain the expertise and experience of those commenting. We would like to thank those who suggested changes to the Nonvascular Extremity Ultrasound LCD . The official notice period for the final LCD begins on April 15, 2009, and the final determination will become effective on July 1, 2009. Comment: A physician from the Indiana Carrier Advisory Committee (CAC) suggested to include the following ICD-9-CM codes: 729.5 – Other disorders of soft tissues, pain in limb; 782.2 – Symptoms involving skin and other integumentary tissue localized superficial swelling, mass, or lump. There are times when the localized superficial code is more appropriately used. Response: The contractor agrees that these diagnoses are consistent with indications in the LCD and the suggested ICD-9-CM codes will be added. _______________________________________________________________________ Comment: A podiatrist suggested adding the following to the “LIMITATIONS” section of the LCD: Neuromas, plantar fasciitis, superficial ganglia, bursae and abscesses unless there is documented evidence of some clinical presentation that obscures the clinician's ability to establish these simple clinical diagnoses. In the case of plantar fasciitis, diagnostic ultrasound is NOT to be used in making an initial determination (diagnosis) and then should ONLY be used after a failed course of conservative management.
    [Show full text]
  • Eosinophilic Fasciitis: Demographics, Disease Pattern and Response to Treatment: Report of 12 Cases and Review of the Literature
    Thomas Jefferson University Jefferson Digital Commons Department of Medicine Faculty Papers Department of Medicine January 2008 Eosinophilic fasciitis: demographics, disease pattern and response to treatment: report of 12 cases and review of the literature Lindsay Bischoff Thomas Jefferson University Chris T. Derk Thomas Jefferson University Follow this and additional works at: https://jdc.jefferson.edu/medfp Part of the Medical Genetics Commons Let us know how access to this document benefits ouy Recommended Citation Bischoff, Lindsay and Derk, Chris T., "Eosinophilic fasciitis: demographics, disease pattern and response to treatment: report of 12 cases and review of the literature" (2008). Department of Medicine Faculty Papers. Paper 27. https://jdc.jefferson.edu/medfp/27 This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Medicine Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: [email protected]. Eosinophilic fasciitis: demographics, disease pattern and response to treatment: report of 12 cases and review of the literature Lindsay Bischoff and Chris T. Derk Lindsay Bischoff Senior Medical Student Jefferson Medical College Correspondence to: Chris T.
    [Show full text]
  • Eosinophilic Fasciitis with Multiple Myeloma: a New Haematological Association D Khanna, a Verity, J M Grossman
    Letters 1111 evidence to support a diagnosis of myasthenia gravis at 2 Gottdiener JS, Sherber HS, Hawley RJ, Engle WK. Cardiac present, we have referred this patient for neurological follow manifestations of polymyositis. Am J Cardiol 1978;41:1131–9. up and review. 3 Lie JT. Cardiac manifestations in polymyositis/dermatomyositis: how to get to the heart of the matter. J Rheumatol 1995;22:809–10. This case demonstrates several of the cardiac manifesta- 4 Miller FM. Current concepts in the idiopathic inflammatory myopathies: tions of polymyositis. It also highlights the possible neurologi- polymyositis, dermatomyositis, and related disorders. Pathogenesis. Ann cal associations with the disease, and the difficulties in subse- Intern Med 1989;111:150–3. quent diagnosis. 5 Aarli, Johan A. Inflammatory myopathy in myasthenia gravis. Current Opin Neurol 1998;11:233–4. 6 Lynch PG. Cardiac involvement in chronic polymyositis. Br Heart J ..................... 1971;33:416–19. Authors’ affiliations 7 Denbow CE, Lie JT, Trancredi RG, Bunch TW. Cardiac involvement in I Morrison, A McEntegart, H Capell, Centre for Rheumatic Disease, polymyositis: a clinicopathologic study of 20 autopsied patients. Arthritis Glasgow Royal Infirmary, Scotland, UK Rhem 1979;22:1088–92. 8 Kehoe RF, Bauernfeind R, Tommaso C, Wyndham C, Rosen KM. Correspondence to: Dr H Capell, Centre for Rheumatic Disease, Glasgow Cardiac conduction defects in polymyositis. Electrophysiologic studies in Royal Infirmary, 84 Castle Street, Glasgow G4 0SF, UK; four patients. Ann Intern Med 1981;94:41–3. [email protected] 9 Oh SJ, Kim DE, Kuruoglu R, Bradley RJ, Dwyer D. Diagnostic sensitivity of the laboratory tests in myasthenia gravis.
    [Show full text]
  • Delayed Diagnosis of Eosinophilic Fasciitis: a Case Report and Review of the Literature
    CASO CLÍNICO Delayed diagnosis of eosinophilic fasciitis: a case report and review of the literature Aydin E 1, Turan Y 1, Yildirim C 1, Tataro ğlu C 1, Çullu E 1, Sendur OF 1 ACTA REUMATOL PORT. 2015;40: 179-184 AbstrAct have a pathogenic role 2-9 . The onset of the symptoms usually present with acute edema and pain in the limbs, Eosinophilic fasciitis (EF) is an uncommon entity cha - followed by thickening of the dermis or subcutaneous racterized by edema, skin thickening and hyperpig - fascia and hyperpigmentation. Skin tightness may pre - mentation of extremities. Laboratory findings are vari - sent with woody induration, “peau d’orange” appear - able and may include peripheral eosinophilia, hyper - ance, and groove sign. Laboratory analysis reveals in - gammaglobulemia, and elevated acute phase reactants. creased eosinophilia, hypergammaglobulinemia and el - A full-thickness skin/fascia/muscle biopsy is the gold evated acute phase reactants in peripheral blood sam - standart for diagnosis. Since EF is an uncommon dis - ples. The definitive diagnosis is based on the presence order and the clinic presentation mimics scleroderma, of inflammatory cell infiltration in the fibrotic fascia, as it takes a long time to make definitive diagnosis. We assessed by a full-thickness skin/fascia/muscle biopsy. present a case diagnosed two years after its onset and Morphea, systemic sclerosis and eosinophilia-myalgia responded well to the treatment. We also include here - syndrome should be consi dered in the differential di - in the results of our literature survey regarding delayed agnosis. The clinical manifestations of EF may suggest diagnosis of Eosinophilic fasciitis.
    [Show full text]
  • Rheumatology
    THE AMERICAN BOARD OF PEDIATRICS® CONTENT OUTLINE Pediatric Rheumatology Subspecialty In-Training, Certification, and Maintenance of Certification (MOC) Examinations INTRODUCTION This document was prepared by the American Board of Pediatrics Subboard of Pediatric Rheumatology for the purpose of developing in-training, certification, and maintenance of certification examinations. The outline defines the body of knowledge from which the Subboard samples to prepare its examinations. The content specification statements located under each category of the outline are used by item writers to develop questions for the examinations; they broadly address the specific elements of knowledge within each section of the outline. Pediatric Rheumatology Each Pediatric Rheumatology exam is built to the same specifications, also known as the blueprint. This blueprint is used to ensure that, for the initial certification and in-training exams, each exam measures the same depth and breadth of content knowledge. Similarly, the blueprint ensures that the same is true for each Maintenance of Certification exam form. The table below shows the percentage of questions from each of the content domains that will appear on an exam. Please note that the percentages are approximate; actual content may vary. Initial Maintenance of Content Domains Certification Certification Exam Exam 1. Core Knowledge in Scholarly Activities 5% 4% 2. Etiology and Pathophysiology 8% 7% 3. Drug Therapy 10% 12% 4. Musculoskeletal Pain 4% 4% 5. Juvenile Arthritis 18% 18% 6. SLE and Related Disorders 12% 12% 7. Idiopathic Inflammatory Myositis 6.5% 6.5% 8. Vasculitis 7% 7% 9. Sclerodermas and Related Disorders 5% 5% 10. Autoinflammatory Diseases 5% 5% 11. Primary Immunodeficiencies and Other 2% 2% Disorders Associated With Inflammatory and Autoimmune Manifestations 12.
    [Show full text]
  • Joints Chapter 8
    Chapter 8 Joints Alessandro Castriota-Scanderbeg, M.D. Joints develop secondarily in the mesenchyme com- Joint Contracture, Joint Stiffness prised between the developing ends of two adjacent bones (mesenchymal interpose) at about 5 1/2 weeks. ᭤ [Limitation (loss) of (active and passive) The mesenchyme is converted to form fibrous tissue, joint motion] hyaline cartilage, or fibrocartilage, depending on whether the developing joint is a fibrous joint, a syn- The issue discussed in the current section encom- chondrosis, or a symphysis, respectively.At the site of passes a heterogeneous group of conditions, both in- a synovial joint, while the primitive mesenchyme of herited and acquired, isolated and associated with the interzone undergoes liquefaction and cavitation, syndromic and nonsyndromic malformation spec- giving rise to the articular cavity, its peripheral con- tra, localized to one joint and generalized. An intro- densation results in formation of the joint capsule duction to the contractural abnormalities developing (Resnick et al.1995).This process is completed by ap- after birth is first provided, followed by a discussion proximately 7 weeks of fetal age, and by 8 weeks of the congenital forms, which represent the main fo- movements of the limbs about the joint are appear- cus of the section. ing. Motion is essential for the normal development Flexion contracture and joint stiffness may occur of joints and contiguous structures. As discussed in as late manifestations of conditions causing joint more detail in the following pages, congenital limita- and/or surrounding tissue infiltration (sarcoidosis, tion or loss of joint function may be caused by factors amyloidosis), hemorrhage (trauma, hemophilia), or that either are intrinsic to the joint, or are extrinsic inflammation (rheumatoid arthritis, systemic lupus but inhibit fetal movements.
    [Show full text]